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Background: The applications of ligand-polyethylene glycol (PEG)-modified nanocarriers have 
now emerged, as well as recognized strategies to provide the vectors with active targeting   properties. 
In this research, premodification and postmodification were compared using the same ligand, ie, 
a novel conjugated mannan-containing PEG and L-α-phosphatidylethanolamine (PE).
Methods: Premodified and postmodified solid lipid nanoparticles were prepared and the 
characteristics of the two kinds of vehicles were evaluated. The modified vectors were then 
administered intravenously to rats and the in vivo targeting behavior of the complexes was 
investigated in liver macrophages.
Results: By carefully formulating the carriers with an optimal ratio of mannan-containing 
PEG-PE, postmodified vehicles displayed more efficient gene expression in rat Kupffer cells 
both in vitro and in vivo.
Conclusion: Postmodified gene carriers are superior to premodified gene vectors, although 
the latter is also promising for targeted gene delivery. This discovery could guide our future 
research.
Keywords: gene therapy, nanomedicine, mannan, polyethylene glycol, L-α-
phosphatidylethanolamine, ligands, premodification, postmodification
Introduction
The prospect of gene nanomedicine holds great promise for alleviation and cure of 
many presently untreatable diseases.1 Ideally, a gene delivery system should be stable, 
biocompatible, nontoxic, cost-effective, and able to be delivered (targeted) to a spe-
cific site, transfer highly anionic exogenous genetic materials, and have maximum 
therapeutic efficacy.2 However, the lack of efficient site-specific delivery systems has 
impeded the realization of gene therapy in practice.3
Compared with viral vectors, nonviral pharmaceutical vectors, such as polymeric 
nanoparticles, liposomes, micelles, nanocapsules, solid lipid nanoparticles (SLN), 
niosomes, and other vectors are potentially less toxic, less immunogenic, relatively 
easy to produce on a large scale, and able to be modified.4–6 Surface modification of 
nanovectors could improve their longevity, bioavailability, targeting ability, and intra-
cellular penetration, and thus provide a range of opportunities for efficient delivery of 
anticancer drugs, genes, and diagnostic agents.7–10
In terms of modification, they could be classified in two different ways, ie, pre-
modification and postmodification. Premodification complexes could be prepared by 
mixing drugs/genes with modified vectors, while postmodification complexes can 
be obtained by surface modification using conventional drug-/gene-loaded carriers.7 
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Examples include the post-pegylated lipoplexes reported by 
Peeters et al to be more promising vehicles for gene delivery 
than pre-pegylated lipoplexes in retinal pigment epithelium 
cells.11 Both premodification and postmodification methods 
have advantages. Premodified vehicles could be more stable, 
and loading of drugs/genes would not change the targeting 
ability of the vectors,12–15 whereas postmodified carriers 
might be modified more efficiently and have better targeting 
capability.16,17 However, which method is better for targeted 
gene delivery is unknown and is a focus of our ongoing 
investigations.
Targeted macrophages are one of the promising strate-
gies for treating diseases such as human immunodeficiency 
virus infection, because macrophages play a major role in 
the immune response to foreign antigens.18 Kupffer cells are 
liver-specific resident macrophages that play an integral part 
in the physiological homeostasis of the liver. They have a 
significant role in the acute and chronic responses of the liver 
to bacterial and viral infections, toxic or carcinogenic attack, 
and mediate hepatotoxicity.19 It has been shown that human 
and murine macrophages express the mannose receptor on 
their surface, and several studies have confirmed the feasi-
bility of using mannose or mannan-modified nanocarriers to 
target macrophages.20
In the present study, a novel conjugated ligand, mannan-
polyethylene glycol- L-α-phosphatidylethanolamine (MN-
PEG-PE) was synthesized, and MN-PEG-PE-modified SLN 
were investigated. In this study we compared the two strate-
gies for modification using the same ligands (MN-PEG-PE) 
in an attempt to identify which kind of nanomedicine is 
preferable for targeted gene therapy, ie, premodified or 
postmodified gene-loaded SLN/DNA. Cationic SLN were 
used as the vectors and plasmid-enhanced green fluorescent 
protein (pEGFP) was used as the model gene. The   properties 
of these two kinds of modified vehicles were compared 
using in vitro and in vivo transfection in a rat Kupffer cell 
model. Unmodified gene-loaded complexes were used as 
controls.
Materials and methods
Materials
Stearic acid, dimethyldioctadecylammonium bromide, 
mannan, PE, concanavalin A (Con A), and MTT (3-[4,5-
dimehyl-2-thiazolyl]-2,5-diphenyl-2H-tetrazolium bromide) 
were purchased from Sigma-Aldrich Co, Ltd (St Louis, MO). 
Injectable soya lecithin was obtained from Shanghai Taiwei 
Pharmaceutical Co, Ltd (Shanghai, China). Butyl carbonyl 
(Boc)-NH-PEG2000-COOH was purchased from Shanghai 
Yarebio Co, Ltd (Shanghai, China). pEGFP-N1 was provided 
by Shandong University (Shandong, China). Quant-iT™ 
PicoGreen® dsDNA quantitation reagent was obtained from 
Invitrogen by Life Technologies (Carlsbad, CA). All other 
chemicals were of analytical grade or higher.
Animals
Adult male Wistar rats (aged 10–12 weeks) were purchased 
from the Medical Animal Test Center of Shandong Province 
and housed under standard laboratory conditions. All animal 
experiments complied with the requirements of the National 
Act on the Use of Experimental Animals (People’s Republic 
of China).
Synthesis of MN-PEG-PE ligands
MN-PEG-PE ligands were synthesized as described in Fig-
ure 1. Boc-NH-PEG-COOH 100 mg was dissolved in dimethyl 
sulfoxide (DMSO) and stirred with PE 36 mg as a mixture. 1-[3-
(dimethylamino)propyl]-3-ethylcarbodiimide (EDC ⋅ HCl) 
72 mg and   triethylamine (1 equivalent of EDC ⋅ HCl) 
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Figure 1 General reaction scheme for synthesis of MN-PEG-PE.
Abbreviations: DMSO, dimethylsulfoxide; MN, mannan; PEG, polyethylene glycol; PE, L-α-phosphatidylethanolamine; TEA, triethylamine.
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were dissolved in DMSO and added dropwise into the 
  mixture in an ice bath and stirred for 36 hours, following 
which concentrated hydrochloric acid was used to detach 
the Boc group, to produce NH2-PEG-CO-NH-PE. Mannan 
100 mg was dissolved in 1 M sodium   hydroxide 1 mL and 
stirred for 30 minutes for   alkalinization.   Chloroacetic acid 
(20%, 1 mL) was then added to the solution and stirred in an 
oil bath at 60°C for 6 hours. After that, 1 M hydrochloric acid 
was added until a pH of 2–3 was reached, to complete the 
carboxymethylation of mannan. Carboxymethylated mannan 
was then stirred with NH2-PEG-CO-NH-PE in DMSO solu-
tion, and EDC ⋅ HCl mixed with triethylamine (1 equivalent of 
EDC ⋅ HCl, in DMSO) was added dropwise into the solution 
in an ice bath and stirred for 24 hours. DMSO was moved 
by rotary evaporation, and the product was dialyzed against 
Milli-Q water (Millipore Corporation, Billerica, MA) for 
24 hours for final formation of MN-PEG-PE.
Preparation of cationic SLN
SLN were prepared using the nanoprecipitation method 
(solvent displacement technique).20–22 Stearic acid 50 mg 
and injectable soya lecithin 30 mg were accurately weighed 
and dissolved in 10 mL of acetone. The organic phase was 
added dropwise into the 0.2%   dimethyldioctadecylammonium 
bromide solution, under stirring at 600 rpm and at room 
  temperature. When complete evaporation of the organic 
  solvent had occurred, the redundant stabilizers were separated 
by ultracentrifugation at 1000 g and at 4°C for 20 minutes. 
The pellet was vortexed and resuspended in Milli-Q water, 
washed three times, filtered through a 0.45 µm membrane, 
and adjusted to pH 7.0 ± 0.2 with sodium hydroxide. The 
SLN suspensions obtained were stored at 2°C–8°C.
Preparation and optimization  
of MN-PEG-PE-modified SLN/DNA
Premodification
Pre-MN-PEG-PE-modified SLN/DNA (A-MN-SLN/DNA) 
complexes were prepared by firstly modifying the SLN with 
MN-PEG-PE to form new vehicles, followed by complex-
ation of the vectors with pEGFP (Figure 2A).
Briefly, MN-PEG-PE ligands were dissolved in 5 mL of 
phosphate-buffered saline (pH 7.4). The solution was then 
added dropwise into 20 mL of SLN and stirred at 600 rpm 
and room temperature, leading to immediate modification. 
Subsequently, free MN-PEG-PE was removed from the mod-
ified SLN/DNA by gel chromatography using a Sephadex® 
G-50 column. The complexes obtained were resuspended 
in Milli-Q water, washed three times, and filtered through a 
membrane with an 0.80 µm pore size to obtain MN-PEG-PE 
modified SLN.
MN-PEG-PE ligands were continuously coated onto the 
surface of the SLN. During the progress of modification, the 
positive surface charge would have been masked, and this 
process caused a decrease in the zeta potential. The optimum 
formulation was obtained when there was no obvious change in 
the potential. To optimize the modification ratio, MN-PEG-PE 
ligands dissolved in phosphate-buffered saline were designed 
at different weight ratios to the SLN (w/w). The change in zeta 
potential of the complexes was determined using a Zetasizer 
Nano-ZS instrument (Malvern, Worcestershire, UK).
A
SLNs
SLNs/DNA
MN-PEG-PE
MN-PEG-PE
MN-SLNs DNA
DNA
A-MN-SLNs/DNA
B-MN-SLNs/DNA SLNs
B
Figure 2 Preparation of pre- (A) and post- (B) MN-PEG-PE-modified SLN/DNA.
Abbreviations: SLN, solid lipid nanoparticles; MN, mannan; PEG, polyethylene glycol; PE, L-α-phosphatidylethanolamine; A-MN-SLNs/DNA, pre-MN-PEG-PE-modified 
SLN/DNA; B-MN-SLNs/DNA, post-MN-PEG-PE-modified SLN/DNA.
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The reporter gene, pEGFP, was mixed with the premodi-
fied SLN by vortexing the suspension with a 1 mg/mL solu-
tion of pEGFP for 20 seconds. Incubation of the mixture for 
30 minutes at room temperature facilitated formation of the 
A-MN-SLN/DNA.
Postmodification
Post-MN-PEG-PE-modified SLN/DNA (B-MN-SLN/DNA) 
complexes were prepared by incubating the SLN with pEGFP 
to form SLN/DNA, followed by modification of SLN/DNA 
with MN-PEG-PE (Figure 2B). Briefly, pEGFP was mixed 
with SLN by vortexing the particles with a 1 mg/mL solu-
tion of pEGFP for 20 seconds. Incubation of the mixture 
for 30 minutes at room temperature facilitated formation of 
SLN/DNA.
MN-PEG-PE ligands were dissolved in 5 mL of 
  phosphate-buffered saline (pH 7.4). The solution was then 
added dropwise to 20 mL of SLN/DNA complexes and 
stirred at 600 rpm in room temperature, leading to immediate 
  modification. Subsequently, free MN-PEG-PE was removed 
from the modified SLN/DNA by gel chromatography using 
a Sephadex G-50 column. The complexes obtained were 
resuspended in Milli-Q water, washed three times, and 
filtered through a membrane with a pore size of 0.80 µm to 
obtain B-MN-SLN/DNA. During this procedure, the MN-
PEG-PE ligands were continuously coated onto the surface 
of the SLN/DNA which would also have caused a decrease 
in the zeta potential. To optimize the modification ratio, 
MN-PEG-PE ligands dissolved in phosphate-buffered saline 
were designed at different weight ratios to the SLN (w/w), 
and the zeta potential of the complexes was determined. 
PEG-PE ligands without mannan were dissolved in 5 mL 
of phosphate-buffered saline and modified onto the SLN/
DNA surface using the same method as described earlier for 
preparation of PEG-PE-SLN/DNA as a control.
Characterization of premodified  
and postmodified SLN/DNA
Gene-loading capacities: PicoGreen  
fluorometry assay
A PicoGreen fluorometry assay was used to quantitate and 
compare the gene-loading abilities of premodified and post-
modified SLN/DNA.23–25 The pEGFP was isolated from the 
A-MN-SLN/DNA and B-MN-SLN/DNA by centrifugation at 
1000 g and 4°C for 20 minutes. The concentration of pEGFP 
was determined by fluorescence, and compared with the 
supernatant from SLN. The amount of pEGFP loaded into 
the SLN was calculated according to the linear calibration 
curve for pEGFP (10 to 2000 ng/mL, R2 = 0.9993). Gene 
loading quantity (%) = (total amount of pEGFP - amount 
of free pEGFP)/total amount of DNA × 100.
Determination of modification: Con A  
agglutination study
Binding of the terminal α-mannose residues to Con A causes 
agglutination of the complexes in solution, resulting in an 
increase in turbidity.26–28 To confirm that the MN-PEG-PE 
ligands were successfully modified onto the SLN/DNA sur-
face, a Con A agglutination assay was performed. Briefly, 
100 µL each of A-MN-SLN/DNA, B-MN-SLN/DNA, and 
unmodified SLN/DNA complexes were added separately 
into 500 µL of Con A (1 mg/mL) in phosphate-buffered 
saline (pH 7.4) with 5 mM of CaCl2 and 5 mM of MgCl2. 
The increase in turbidity at 360 nm (OD360) was monitored 
for 180 seconds.
Isolation and culture of Kupffer cells
Kupffer cells were isolated from Wistar rats under pentobar-
bitone anesthesia using a method described elsewhere.29 The 
rat portal veins were cannulated and perfused with Hank’s 
buffered salt solution for 10 minutes at room temperature. 
During this time, the liver was excised and the perfusate 
discarded. The liver was then perfused with 0.2% pronase 
(60 mL at room temperature) which was discarded. Next, 
the liver was perfused with a recirculating solution of 0.05% 
pronase and 0.05% collagenase (60 mL at room temperature) 
until the liver was digested, as judged by softening of the 
liver parenchyma beneath the capsule. The liver was then cut 
into small pieces, suspended in 100 mL of solution contain-
ing 0.02% pronase, 0.05% collagenase, and 0.005% DNase, 
and agitated at room temperature for 20 minutes. Following 
digestion, the liver homogenate was filtered through sterile 
gauze and centrifuged (at 1000 g and 4°C for 10 minutes). 
The supernatant was removed and the pellet was resuspended 
in 10 mL of Percoll gradient. Aliquots (5 mL) of this cell 
suspension were added to 5 mL aliquots of Percoll gradi-
ent. These were carefully overlaid with 5 mL of Hank’s 
buffered salt solution and centrifuged at 1000 g and 4°C 
for 20   minutes. The nonparenchymal cell-enriched layer 
observed at the interface between the two layers was carefully 
harvested and diluted with 10 mL of Hank’s buffered salt 
solution. The suspension was then centrifuged (1000 g and 
4°C for 20 minutes) to precipitate the Kupffer cells, which 
were then seeded into a 96-well microtiter plate at a density 
of 2 × 104 cells/well in 200 µL RPMI-1640 supplemented 
with 10% fetal bovine serum and antibiotics. After incubation 
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at 37°C for 2 hours in a 5% CO2 atmosphere, the culture 
medium was replaced by 200 µL of fresh RPMI-1640 to 
yield the purified Kupffer cells.
The isolated rat liver Kupffer cells were defined, and 
about 8.15 × 107 cells were obtained, with a purity of 
about 91.2% (8.94 × 107/rat liver nonparenchymal cells). 
The isolated and purified rat Kupffer cells retained their 
in vivo morphological, biological, and immunological 
characteristics.
In vitro cytotoxicity evaluation
The in vitro cytotoxicity of A-MN-SLN/DNA and B-MN-
SLN/DNA against Kupffer cells was evaluated by MTT 
assay.30 The Kupffer cells were incubated with modified and 
unmodified SLN/DNA at various concentrations (10, 20, 50, 
100, and 200 µg/mL) for 48 hours at 37°C and in a 5% CO2 
atmosphere. Cell viability was then assessed by MTT assay. 
Next, MTT 5 mg/mL in phosphate-buffered saline was added 
to each well and the plate was incubated for a further 4 hours 
at 37°C in a 5% CO2 atmosphere. The MTT containing the 
medium was then removed, and the crystals formed by living 
cells were dissolved in 100 µL of DMSO. The absorbance at 
570 nm was determined by a microplate reader. Untreated 
cells were taken as a control with 100% viability, and cells 
without the addition of MTT were used as a blank to calibrate 
the spectrophotometer to zero absorbance. The relative cell 
viability (%) compared with control cells was calculated 
using (Abssample/Abscontrol) × 100.
In vitro release of MN-SLN/DNA
The in vitro release studies of premodified and postmodi-
fied MN-SLN/DNA were performed in phosphate-buffered 
saline (pH 7.4).31 Typically, aliquots of complexes were sus-
pended in 1 mL of phosphate-buffered saline (in Eppendorf® 
tubes) and vortexed for 30 seconds. The tubes were then 
placed in a 37°C shaking water bath at 100 rpm. Separate 
tubes were used for different data points. At predetermined 
time intervals, the suspensions were centrifuged at 1 500 g 
for 30 minutes, and the amount of DNA released in the 
supernatant was analyzed using the PicoGreen assay. 
  Background readings were obtained using the supernatants 
from the blank SLN.
In vitro transfection analysis
The Kupffer cells were seeded into 24-well plates at a 
density of 8 × 104 cells/well in 1 mL of RPMI-1640 with 
10% fetal bovine serum. After about 24 hours, the medium 
was replaced by 500 µL of transfection medium   containing 
A-MN-SLN/DNA and B-MN-SLN/DNA. Unmodified 
SLN/DNA complexes and PEG-PE ligand-modified SLN/
DNA without mannan (PEG-PE-SLN/DNA) were used as 
controls. The original incubation medium was replaced 
with 1 mL of complete medium after incubation at 37°C 
for 4 hours in a 5% CO2 atmosphere. The cells were 
incubated and studied until 72 hours after transfection. 
The fluorescent cells were observed using an inversion 
fluorescence microscope, at which time pictures were 
taken for the record.
In vivo gene delivery
Adult male Wistar rats were divided into five groups (six rats 
in each group) and injected intravenously with 1 mL of 
naked DNA, SLN/DNA, PEG-PE-SLN/DNA, A-MN-SLN/
DNA, or B-MN-SLN/DNA (containing 60 µg of pEGFP). 
At predetermined time intervals (24, 48, and 72 hours), the 
rats were euthanized and their Kupffer cells were isolated 
and cultured as described earlier. The fluorescent cells were 
observed using an inversion fluorescence microscope, at 
which time pictures were taken for the record. After that, the 
cells were washed with 1 mL of phosphate-buffered saline 
(100 g and 4°C for 5 minutes) and were detached with trypsin/
EDTA. The supernatant was discarded and resuspended with 
300 µL of phosphate-buffered saline and added into the flow 
cytometer to quantitate the amount of Kupffer cells which 
has been successfully transfected.
Statistical analysis
All studies were repeated three times and the measurements 
were carried out in triplicate. Results were reported as the 
mean ± standard deviation. Statistical significance was ana-
lyzed using the Student’s t-test. Differences between experi-
mental groups were considered significant at P , 0.05.
Results
Structure confirmation of MN-PEG-PE 
ligands
The structure of MN-PEG-PE was confirmed by infrared 
spectroscopy and nuclear magnetic resonance (1H NMR) 
spectroscopy. Infrared ν/cm-1: 3517.3 (–NH–, –OH); 1820.4 
(–C=O); 1667.9 (–HN–CO–); 1635.2 (–HN–CO–, evidence 
of the mannan linked with PEG-PE); and 1093.2 (–C–O–C–, 
  secondary alcohol structure in mannan). 1H NMR (DMSO-d6, 
300 MHz) δ: 2.47 (CH2CO), 3.26 (CH2N) 6.05 (NH), and 
δ (3.0–6.5). Similar peaks were observed as the spectra of 
mannan, ie, δ (0–3.0), and the peaks were in accordance with 
PEG-PE. The production rate was around 70%.
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Optimization of modification ratio  
and quantitation of binding capacity
The optimization of ligand to carrier ratio and binding capac-
ity of the optimized vectors were as follows:
Premodified SLN/DNA
MN-PEG-PE ligands were previously coated onto the SLN 
surface. The ratio of ligands to carriers was optimized by mea-
suring the change in zeta potential. As illustrated in Figure 3A, 
the optimized ratio of MN-PEG-PE to SLN was 40%. This 
ratio was used for further experiments. MN-SLN were then 
incubated with pEGFP to form A-MN-SLN/DNA. The gene 
loading efficiency of A-MN-SLN/DNA was around 80%.
Postmodified SLN/DNA
SLN were firstly incubated with pEGFP to form SLN/DNA. 
The MN-PEG-PE ligands were next coated onto the SLN/DNA 
surface to form B-MN-SLN/DNA. As shown in Figure 3B, the 
optimized ratio of MN-PEG-PE to SLN/DNA was 40%. This 
ratio was used for the further experiments. The gene loading 
efficiency of B-MN-SLN/DNA was around 87%.
Characterization of premodified  
and postmodified MN-SLN/DNA
The mean particle size, polydispersity index, and zeta 
potential of SLN, MN-SLN, SLN/DNA, A-MN-SLN/DNA, 
and B-MN-SLN/DNA were characterized and are shown in 
Table 1.
Determination of MN-PEG-PE 
modification
A Con A agglutination assay was used to confirm further that 
the MN-PEG-PE ligands were successfully modified onto the 
vector surface. As shown in Figure 4, the turbidity of A-MN-
SLN/DNA and B-MN-SLN/DNA appeared to increase, while 
the SLN and SLN/DNA formulations appeared to show no 
significant increase in turbidity.
In vitro cytotoxicity evaluation
The in vitro cytotoxicity of A-MN-SLN/DNA and B-MN-
SLN/DNA against Kupffer cells was evaluated at various 
concentrations by MTT assay. The cell viability of the vectors 
over the studied concentration range (10–200 µg/mL) was 
between 80% and 100% compared with controls (Figure 5).
In vitro release and in vitro  
transfection analysis
The in vitro release profiles for A-MN-SLN/DNA and B-MN-
SLN/DNA are shown in Figure 6. Both the premodified and 
postmodified SLN/DNA reached over 80% gene release after 
72 hours. The in vitro transfection efficiency of A-MN-SLN/
DNA and B-MN-SLN/DNA in Kupffer cells after 72 hours 
of transfection was analyzed and compared with naked DNA, 
unmodified SLN/DNA, and PEG-PE-SLN/DNA (Figure 7). 
B-MN-SLN/DNA showed higher transfection efficiency 
than A-MN-SLN/DNA at 48 and 72 hours after transfection 
(P , 0.05).
In vivo gene delivery
The in vivo transfection efficiency of A-MN-SLN/DNA and 
B-MN-SLN/DNA was observed and is shown in   Figure 8. 
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Figure 3 Optimization of the modification ratios for (A) pre-MN-PEG-PE-modified 
SLN/DNA and (B) post-MN-PEG-PE-modified SLN/DNA.
Abbreviations: SLN, solid lipid nanoparticles; MN, mannan; PEG, polyethylene 
glycol; PE, L-α-phosphatidylethanolamine.
Table 1 Particle size and zeta potential of different vectors
Characteristics/ 
samples
Mean particle 
size (nm)
Polydispersity  
index
Zeta potential   
(mV)
SLN 87.5 ± 5.2 0.11 ± 0.02 +45.2 ± 1.5
MN-SLN 153.1 ± 4.3 0.20 ± 0.02 +28.5 ± 2.3
SLN/DNA 121.8 ± 5.8 0.15 ± 0.03 +33.1 ± 2.4
Pre-MN-PEG- 
PE-modified  
SLN/DNA
223.6 ± 5.3 0.22 ± 0.05 +20.4 ± 2.1
Post-MN-PEG- 
PE-modified  
SLN/DNA
185.2 ± 4.1 0.11 ± 0.04 +21.3 ± 1.7
Abbreviations: SLN, solid lipid nanoparticles; MN, mannan; PEG, polyethylene 
glycol; PE, L-α-phosphatidylethanolamine.
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B-MN-SLN/DNA had higher transfection efficiency at 
different time intervals compared with the other vectors. 
Flow cytometry was used to quantitate further the amount 
of cells which had been successfully transfected. As shown 
in Figure 9, B-MN-SLN/DNA showed a remarkably higher 
transfection efficiency compared with A-MN-SLN/DNA and 
unmodified SLN/DNA (P , 0.05).
Discussion
The applications of ligand-PEG modification of nanocarri-
ers have emerged as well recognized strategies to provide 
these vectors with active targeting properties using a wide 
assortment of covalently attached targeting ligands.32 A series 
of PEG-PE conjugates has been used for the modification 
of various vehicles to create active targeting nanocarriers 
capable of spontaneous accumulation at specific sites.33–36 
In this research, novel conjugated mannan-containing 
PEG-PE ligands were synthesized and MN-PEG-PE-
modified SLN were investigated. Here, mannan is the target 
moiety which can bind to the mannose receptor in the mac-
rophage, and PEG-PE is the spacer linked onto the surface of 
the SLN. It has been suggested that the length and flexibility 
of the spacer between the carbohydrate head group and carrier 
surface mainly influences the target specificity and uptake 
of vectors by macrophages.37 Use of PEG-PE conjugates has 
been reported and TATp-PEG2000-PE conjugates have been 
applied for modification of nanocarriers to form active target-
ing vectors,38 so PEG2000-PE was used as the anchor.
In our research, we are investigating which form of 
modification is better, ie, premodification to form newly 
modified vectors or postmodification after DNA has been 
loaded. In this study, we compared the two methods of 
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Figure 7 In vitro transfection efficiency of A-MN-SLN/DNA and B-MN-SLN/DNA in Kupffer cells after transfection for 24, 48, and 72 hours.
Abbreviations:  SLN,  solid  lipid  nanoparticles;  A-MN-SLNs/DNA,  pre-MN-PEG-PE-modified  SLN/DNA;  B-MN-SLNs/DNA,  post-MN-PEG-PE-modified  SLN/DNA; 
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Figure 6 In vitro release profiles of A-MN-SLN/DNA and B-MN-SLN/DNA.
Abbreviations: SLN, solid lipid nanoparticles; A-MN-SLNs/DNA, pre-MN-PEG-
PE-modified SLN/DNA; B-MN-SLNs/DNA, post-MN-PEG-PE-modified SLN/DNA; 
MN, mannan; PEG, polyethylene glycol; PE, L-α-phosphatidylethanolamine; pEGFP, 
plasmid-enhanced green fluorescent protein.
modification using the same ligands. Our investigation began 
with preparation and optimization of the MN-PEG-PE modi-
fication ratio for the two kinds of modification. As shown in 
Figure 3, A-MN-SLN/DNA refers to SLN which had been 
previously modified by MN-PEG-PE to form MN-SLN and 
then incubated with pEGFP; whereas B-MN-SLN/DNA 
were prepared by firstly binding DNA with SLN followed 
by coating of the MN-PEG-PE ligands. The modification 
ratios of A-MN-SLN/DNA and B-MN-SLN/DNA were 
approximately the same (40%, ligands/vectors, w/w). The 
gene loading efficiency of B-MN-SLN/DNA was slightly 
higher than that of A-MN-SLN/DNA (80%–87%). This may 
be explained as follows. The complexation of genes by SLN 
was void-free, and subsequent coating of ligands did not 
affect the gene binding capacity, whereas premodified SLN 
were coated with ligands first and this may have had some 
influence on gene complexation caused a slight decrease in 
loading efficacy.
When the modification ratios of the two kinds of vectors 
had been determined, A-MN-SLN/DNA and B-MN-SLN/
DNA were prepared and characterized. The mean particle 
sizes of A-MN-SLN/DNA and B-MN-SLN/DNA were about 
223 nm and 185 nm, respectively. The premodified vectors 
was larger than the postmodified vectors, which might be 
because complexation of A-MN-SLN with DNA was not as 
tight as for B-MN-SLN/DNA. The polydispersity index of 
B-MN-SLN/DNA was smaller than for A-MN-SLN/DNA, 
which had a relatively narrow size distribution. These differ-
ences in physical properties may have affected the chemical 
characteristics of the vehicles. The zeta potentials of the two 
types of carrier were approximately +20 mV , and the posi-
tive surface charge could have enhanced the combination 
of the vectors with the negative charged cell surfaces and 
facilitated endocytosis.
Con A was the first legume lectin recognized as one of 
the mannose-specific lectins, and is believed to play a role 
in recognition of mannose-containing vectors.39,40 It has 
been used extensively for evaluation of glycoconjugates.41,42 
Binding of the terminal α-mannose residues to Con A causes 
agglutination of the complexes in solution, resulting in an 
increase in turbidity. As shown in Figure 4, when incubated 
with Con A solution, both A-MN-SLN/DNA and B-MN-
SLN/DNA appeared to show an increase in turbidity, 
whereas SLN and SLN/DNA formulations appeared to show 
no significant increase in turbidity. This could be evidence 
of the success of mannan-containing ligands modified onto 
an SLN surface using both premodification and postmodi-
fication methods.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
2026
Jiang et alInternational Journal of Nanomedicine 2012:7
An in vitro release study was carried out in order to show 
the release profiles of the two kinds of vectors. The release of 
premodified carriers was faster during the 48 hours of study 
 ( Figure 6), which may be because the complex was not as tight 
as for the postmodified vehicles, and DNA release from SLN 
was easier. After 48 hours, the accumulated gene release from 
B-MN-SLN/DNA caught up with the steps of A-MN-SLN/DNA. 
Both the premodified and postmodified SLN/DNA reached 
over 80% gene release at 72 hours. Could the faster release of 
A-MN-SLN/DNA during 48 hours win some efficiency at the 
same time points in transfection studies? Or maybe the compact 
B-MN-SLN/DNA would be more effective?
Kupffer cells are liver-specific resident macrophages 
that play an integral part in the physiological homeostasis 
A
B
C
D
E
24 48
Time (hours)
72
Figure 8 Fluorescent images of Kupffer cells transfected with naked pEGFP (A), SLN/DNA (B), PEG-PE-SLN/DNA (C), A-MN-SLN/DNA (D), and B-MN-SLN/DNA (E) at 
24, 48, and 72 hours after transfection.
Abbreviations: SLN, solid lipid nanoparticles; A-MN-SLNs/DNA, pre-MN-PEG-PE-modified SLN/DNA; B-MN-SLNs/DNA, post-MN-PEG-PE-modified SLN/DNA; MN, 
mannan; PEG, polyethylene glycol; PE, L-α-phosphatidylethanolamine; pEGFP, plasmid-enhanced green fluorescent protein.
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of the liver. In this study, rat Kupffer cells were isolated and 
used as model cells for in vitro cytotoxicity evaluation and 
transfection analysis. As shown in Figure 7, modified carri-
ers showed obviously higher efficiency than PEG-PE- SLN/
DNA, unmodified SLN/DNA, or naked DNA (P , 0.05). 
At 24 hours after transfection, the transfection ability of 
A-MN-SLN/DNA and B-MN-SLN/DNA was almost the 
same (P . 0.05). A-MN-SLN/DNA showed higher transfec-
tion efficiency than B-MN-SLN/DNA at 48 and 72 hours 
following transfection (P , 0.05). The results are interesting 
here because the in vitro release of A-MN-SLN/DNA was 
less than for B-MN-SLN/DNA at 48 hours, while the in vitro 
transfection efficiency was better. Could this phenomenon 
be evidence of better targeting ability for the postmodified 
system? This question should be answered on completion of 
our in vivo gene delivery studies.
In vivo gene delivery and expression assays were used 
in an animal model to compare the gene-delivering ability of 
premodified and postmodified gene vectors. After intravenous 
injection, rats in this study were euthanized, and their Kupffer 
cells were isolated and analyzed using inverted fluorescence 
microscopy (Figure 8) and flow cytometry (Figure 9). 
B-MN-SLN/DNA showed better transfection efficiency than 
A-MN-SLN/DNA at 24, 48, and 72 hours. These results dem-
onstrate that the postmodified SLN had more significant target-
ing ability for rat liver Kupffer cells, could deliver more genes 
into the cells, and displayed higher transfection efficiency. The 
high transfection efficiency at 72 hours after injection indicates 
the controlled-release features of the vehicles.
This in vitro and in vivo evidence of gene transfection 
strongly supports the active targeting ability of mannan-
  containing PEG-PE-modified gene-loaded SLN. Moreover, the 
results indicate that postmodified gene carriers are superior to 
premodified gene vectors, although the latter are also promis-
ing for targeted gene delivery. This observation will guide 
our future research, and could be a reference for modification 
of nanocarriers for targeted gene delivery.
Conclusion
The results of this study are consistent with the observations 
of other researchers in this area, ie, that mannose-mediated 
targeting can successfully deliver genes into cells that express 
the mannose receptor. We conclude that postmodifica-
tion of gene-loaded nanomedicine has an advantage over 
  premodification. By carefully formulating the carriers with 
an optimal ratio of MN-PEG-PE, postmodified vehicles 
displayed more efficient gene expression in rat Kupffer cells 
both in vitro and in vivo. This evidence strongly supports 
the active targeting ability of mannan-containing PEG-PE-
modified gene carriers. Most importantly, the proof of supe-
riority of postmodified gene delivery vectors has provided a 
reference point for further studies on this area.
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Supplementary data
In vivo gene delivery (Figure 9)
Details of the experiments and data analysis are as follows: 
Cells were washed in cold phosphate-buffered saline three 
times and the fluorescence intensity of the cells was deter-
mined using a flow cytometer equipped with a 488 nm argon 
laser for excitation. For each sample, about 10,000 events 
were collected and fluorescence was detected. Signals were 
amplified in logarithmic mode for fluorescence to determine 
the positive events by a standard gating technique. The 
percentage of positive events was calculated as the events 
within the gate divided by the total number of events, 
excluding cell debris. The percentage of cells transfected 
with plasmid-enhanced green fluorescent protein appeared 
at the upper right and lower right quadrants of the diagram. 
The data for the quadrantal diagram of the in vivo study 
are as follows:
1.  Naked plasmid-enhanced green fluorescent protein 
24 hours post transfection
Quad X mean Y mean Events%Total%Gated
1.  UL 6.8 18.3 5 0.04 74.01
2.  UR 107.6 78.6 31 0.26 1.18
3.  LL 2.4 8.5 11986 97.42 24.33
4.  LR 43.8 14.1 65 0.54 0.47
Gene expression UR + LR = 1.65%
2.  Naked plasmid-enhanced green fluorescent protein 
48 hours post transfection
Quad X mean Y mean Events%Total%Gated
1.  UL 6.8 18.3 5 0.04 69.27
2.  UR 107.6 78.6 31 0.26 2.03
3.  LL 2.4 8.5 11986 97.42 28.38
4.  LR 43.8 14.1 65 0.54 0.32
Gene expression: UR + LR = 2.35%
3.  Naked plasmid-enhanced green fluorescent protein 
72 hours post transfection
Quad X mean Y mean Events%Total%Gated
1.  UL 6.8 18.3 5 0.04 71.36
2.  UR 107.6 78.6 31 0.26 1.47
3.  LL 2.4 8.5 11986 97.42 26.39
4.  LR 43.8 14.1 65 0.54 0.75
Gene expression: UR + LR = 2.22%
4.  SLN/DNA 24 hours post transfection
Quad X mean Y mean Events%Total%Gated
1.  UL 6.8 18.3 5 0.04 61.72
2.  UR 107.6 78.6 31 0.26 5.56
3.  LL 2.4 8.5 11986 97.42 27.86
4.  LR 43.8 14.1 65 0.54 4.86
Gene expression: UR + LR = 10.42%
5.  SLN/DNA 48 hours post transfection
Quad X mean Y mean Events%Total%Gated
1.  UL 6.8 18.3 5 0.04 58.24
2.  UR 107.6 78.6 31 0.26 12.41
3.  LL 2.4 8.5 11986 97.42 23.79
4.  LR 43.8 14.1 65 0.54 5.52
Gene expression: UR + LR = 17.93%
6.  SLN/DNA 72 hours post transfection
Quad X mean Y mean Events%Total%Gated
1.  UL 6.8 18.3 5 0.04 58.24
2.  UR 107.6 78.6 31 0.26 12.41
3.  LL 2.4 8.5 11986 97.42 23.79
4.  LR 43.8 14.1 65 0.54 5.52
Gene expression: UR + LR = 17.93%
7.  PEG-PE-SLN/DNA 24 hours post transfection
Quad X mean Y mean Events%Total%Gated
1.  UL 6.8 18.3 5 0.04 70.06
2.  UR 107.6 78.6 31 0.26 6.40
3.  LL 2.4 8.5 11986 97.42 18.61
4.  LR 43.8 14.1 65 0.54 4.93
Gene expression: UR + LR = 11.33%
8.  PEG-PE-SLN/DNA 48 hours post transfection
Quad X mean Y mean Events%Total%Gated
1.  UL 6.8 18.3 5 0.04 52.16
2.  UR 107.6 78.6 31 0.26 16.87
3.  LL 2.4 8.5 11986 97.42 25.30
4.  LR 43.8 14.1 65 0.54 5.65
Gene expression: UR + LR = 22.52%
9.  PEG-PE-SLN/DNA 72 hours post transfection
Quad X mean Y mean Events%Total%Gated
1.  UL 6.8 18.3 5 0.04 49.35
2.  UR 107.6 78.6 31 0.26 19.08
3.  LL 2.4 8.5 11986 97.42 25.05
4.  LR 43.8 14.1 65 0.54 6.52
Gene expression: UR + LR = 25.6%
10.  A-MN-SLN/DNA 24 hours post transfection
Quad X mean Y mean Events%Total%Gated
1.  UL 6.8 18.3 5 0.04 57.53
2.  UR 107.6 78.6 31 0.26 11.42
3.  LL 2.4 8.5 11986 97.42 22.82
4.  LR 43.8 14.1 65 0.54 8.23
Gene expression: UR + LR = 19.65%
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11.  A-MN-SLN/DNA 48 hours post transfection
Quad X mean Y mean Events%Total%Gated
1.  UL 6.8 18.3 5 0.04 46.36
2.  UR 107.6 78.6 31 0.26 22.48
3.  LL 2.4 8.5 11986 97.42 25.25
4.  LR 43.8 14.1 65 0.54 5.88
Gene expression: UR + LR = 28.36%
12.  A-MN-SLN/DNA 72 hours post transfection
Quad X mean Y mean Events%Total%Gated
1.  UL 6.8 18.3 5 0.04 48.78
2.  UR 107.6 78.6 31 0.26 20.93
3.  LL 2.4 8.5 11986 97.42 20.77
4.  LR 43.8 14.1 65 0.54 9.52
Gene expression: UR + LR = 30.45%
13.  B-MN-SLN/DNA 24 hours post transfection
Quad X mean Y mean Events%Total%Gated
1.  UL 6.8 18.3 5 0.04 49.74
2.  UR 107.6 78.6 31 0.26 17.78
3.  LL 2.4 8.5 11986 97.42 23.14
4.  LR 43.8 14.1 65 0.54 9.34
Gene expression: UR + LR = 27.12%
14.  B-MN-SLN/DNA 48 hours post transfection
Quad X mean Y mean Events%Total%Gated
1.  UL 6.8 18.3 5 0.04 44.73
2.  UR 107.6 78.6 31 0.26 25.15
3.  LL 2.4 8.5 11986 97.42 17.21
4.  LR 43.8 14.1 65 0.54 12.88
Gene expression: UR + LR = 38.03%
15.  B-MN-SLN/DNA 72 hours post transfection
Quad X mean Y mean Events%Total%Gated
1.  UL 6.8 18.3 5 0.04 37.26
2.  UR 107.6 78.6 31 0.26 32.67
3.  LL 2.4 8.5 11986 97.42 19.23
4.  LR 43.8 14.1 65 0.54 10.83
Gene expression: UR + LR = 43.5%
Abbreviations
UL, upper left; UR, upper right; LL, lower left; LR, lower 
right; SLN, solid lipid nanoparticles; A-MN-SLN/DNA, 
pre-MN-PEG-PE-modified SLN/DNA; B-MN-SLN/DNA, 
post-MN-PEG-PE-modified SLN/DNA; MN, mannan; PEG, 
polyethylene glycol; PE, L-α-phosphatidylethanolamine; 
pEGFP, plasmid-enhanced green fluorescent protein.
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